A closed loop insulin pump is a system that automatically adjusts insulin delivery based on real-time glucose readings, acting as a kind of artificial pancreas. It combines three pieces of technology: a continuous glucose monitor (CGM) worn on the body, a control algorithm that makes dosing decisions, and an insulin pump that delivers the insulin. All three components communicate wirelessly via Bluetooth, creating a feedback loop that raises or lowers insulin delivery without you having to intervene for most of the day.
How the Three Components Work Together
The CGM is a small sensor inserted just under the skin, usually on the arm or abdomen. It measures glucose levels in the fluid between your cells every few minutes, then sends that data wirelessly to the algorithm. The algorithm, which can live inside the pump itself, on a separate handheld device, or even on a smartphone app, interprets the glucose trend and decides how much insulin to deliver. It then tells the pump to increase, decrease, or stop insulin flow accordingly.
This cycle repeats continuously, adjusting your insulin every few minutes around the clock. The result is tighter glucose control than most people can achieve on their own, especially overnight and between meals when blood sugar can drift without you noticing.
Hybrid vs. Fully Closed Loop
Most systems on the market today are “hybrid” closed loop systems. The word hybrid means the system handles background insulin automatically, but you still need to tell it when you eat and roughly how many carbohydrates are in your meal. You enter that information, the pump delivers a mealtime dose, and the algorithm fine-tunes your insulin in the hours that follow. Carbohydrate counting remains a daily task with these systems, and some users find that the algorithm’s decisions aren’t always transparent.
Fully closed loop systems aim to eliminate that manual step entirely. They deliver all insulin automatically, with no meal announcements or carbohydrate counting required. The trade-off is that the system can’t anticipate a meal the way you can, so blood sugar may spike higher after eating before the algorithm catches up. An eight-week trial in adults with type 2 diabetes found that a fully closed loop pump safely managed blood sugar without any mealtime input, and participants highlighted the elimination of injections and finger-prick testing as key benefits. These systems are still newer and less widely available than hybrid models.
Systems Currently Available
The first automated insulin delivery system, the Medtronic 670G, received FDA clearance in 2016. Since then, several more have reached the market. The major systems now include the Medtronic 780G, Tandem Control-IQ, Omnipod 5, and the iLet Bionic Pancreas. Tidepool Loop, based on an open-source design, was also recently FDA-cleared. Each system pairs with specific CGM brands and has its own interface, so the choice often comes down to personal preference, insurance coverage, and whether you want a tubed pump or a tubeless pod.
Open-source, do-it-yourself loop systems also exist. These are built by users who connect commercially available pumps and sensors through community-developed algorithms. The American Diabetes Association’s 2025 standards of care acknowledge these systems and recommend that healthcare providers support patients who choose to use them.
How the Algorithm Decides Your Dose
The two main approaches algorithms use are called model predictive control and proportional-integral-derivative control. In practical terms, one approach (model predictive control) builds a small mathematical model of how your body responds to insulin and uses it to predict where your glucose is heading, then adjusts delivery to steer toward a target. The other reacts to how far your glucose is from the target, how fast it’s changing, and how long it’s been off-target.
A head-to-head clinical trial comparing the two found that model predictive control achieved nearly 75% time in the target glucose range, including during meals the system wasn’t told about. In practice, different commercial pumps use different algorithmic strategies, but all of them learn from your patterns over time and become more personalized the longer you wear them.
Safety Features That Prevent Lows
One of the most important capabilities of these systems is preventing dangerously low blood sugar. The simplest version of this is low-glucose suspend: when your glucose drops below a set threshold, the pump automatically stops delivering insulin without needing any confirmation from you.
More advanced systems use predictive low-glucose suspend, which looks at your glucose trend and can predict a low up to 30 minutes before it happens. The pump pre-emptively reduces or stops insulin before you actually go low. Some experimental systems take this further with dual-hormone delivery, adding small doses of glucagon (a hormone that raises blood sugar) because actively pushing glucose up works faster than simply stopping insulin and waiting for levels to recover on their own.
What the Clinical Evidence Shows
Closed loop systems consistently improve time in range, which is the percentage of the day your blood sugar stays between roughly 70 and 180 mg/dL. In a trial of very young children with type 1 diabetes, hybrid closed loop use over 18 months increased time in range by about 8.4 percentage points compared to a standard sensor-augmented pump. That may sound modest, but in glucose management it translates to roughly two extra hours per day spent in a healthy range.
A1c levels, the standard measure of average blood sugar over two to three months, also improve. A real-world study of 71 adults with poorly controlled type 1 diabetes found that starting an advanced hybrid closed loop system dropped average A1c from 7.2% to 6.8%. These improvements come with less time spent in dangerous low ranges, meaning the systems don’t achieve tighter control by simply flooding the body with more insulin.
What You Still Need to Do
With a hybrid system, you still count carbohydrates and enter meal boluses. You also need to change the pump’s infusion site every two to three days, replace or recharge the CGM sensor on its schedule, and calibrate the system if required by the specific device. You’ll carry or wear the pump and sensor at all times, and you’ll interact with the system through a screen on the pump or a smartphone app.
Some users report frustration with not fully understanding why the algorithm makes certain decisions, particularly when it overrides their expectations. Learning to trust the system and resist the urge to constantly override it is a real adjustment. That said, the 2025 ADA Standards of Care now recommend automated insulin delivery as the preferred method of insulin delivery for people with type 1 diabetes, noting that these systems have largely replaced older pump approaches because of their advantages in reducing both highs and lows.
Who These Systems Are For
Closed loop systems are primarily used by people with type 1 diabetes, including children as young as two years old depending on the device. The ADA also recommends offering insulin pump therapy, preferably with CGM, to people with type 2 diabetes who are on multiple daily injections and can use the device safely. Fully closed loop trials in type 2 diabetes have shown promising results, and this is an area where access is expanding. The choice of system should be based on individual circumstances, preferences, and needs, whether the person manages the device independently or with the help of a caregiver.